Can statins be used in patients with end‑stage renal disease (ESRD)?

Statin Use in ESRD: A Stage-Dependent Approach

Do not initiate statins in patients already on dialysis, but continue statins in patients who were taking them before dialysis started.

The Critical Distinction: Dialysis vs. Pre-Dialysis CKD

The evidence clearly shows that timing of statin initiation relative to dialysis status is the key decision point, not simply the presence of ESRD 1, 2.

For Patients NOT Yet on Dialysis (CKD Stages 1-5, non-dialysis)

• Strongly recommend statin initiation in adults 40-75 years with LDL-C 70-189 mg/dL and 10-year ASCVD risk ≥7.5% 2
• CKD itself is a risk-enhancing factor that favors statin therapy 2
• The absolute cardiovascular benefit is actually larger in CKD patients due to their higher baseline cardiovascular risk 1
• Statins reduce relative risk of cardiovascular events similarly in patients with and without CKD 1

For Patients Already on Dialysis

If statin-naive (never on statins):

• Do not initiate statins - this is a Class III (No Benefit) recommendation 2
• Three large trials failed to show conclusive benefit in prevalent dialysis patients 1
• The magnitude of any relative risk reduction is substantially smaller than in earlier CKD stages 1

If already taking statins when dialysis starts:

• Continue the statin - Grade 2C recommendation 1, Class IIb (may be reasonable) 2
• In the SHARP trial, 34% of patients transitioned to dialysis during the study and overall benefit was observed when analyzed as "non-dialysis" patients 1
• The rationale: incident dialysis patients may be systematically different from prevalent dialysis patients 1

The Evidence Behind This Approach

The guidelines prioritize two key observations:

1. The "dialysis divide": Multiple large RCTs (4D, AURORA, SHARP dialysis subgroup) showed minimal to no benefit when initiating statins in patients already established on dialysis 1, 2, 3

2. The transition period matters: Patients who start statins before dialysis and continue through dialysis initiation appear to derive continued benefit, likely because they represent a different risk profile 1

Special Considerations

Kidney Transplant Recipients

• Suggest statin treatment (Grade 2A) 1
• Cardiovascular death or non-fatal MI rate is approximately 21.5 per 1000 patient-years - substantially elevated risk 1

Exceptions Where Statin Initiation in Dialysis Might Be Considered

While guidelines recommend against routine initiation, individual patients might consider statins if 1:

• Very high LDL-C levels (though evidence remains speculative)
• Recent cardiovascular event (MI or stroke)
• Younger patients with longer life expectancy
• Understanding that benefit is uncertain and small

Common Pitfalls to Avoid

1. Don't automatically stop statins at dialysis initiation - this is the most common error. The recommendation is to continue, not discontinue 1, 2

2. Don't confuse "prevalent" vs "incident" dialysis patients - someone newly starting dialysis while on a statin is different from someone established on dialysis for years 1

3. Don't use LDL-C targets to drive decisions in dialysis patients - the lipid hypothesis doesn't apply the same way in ESRD 1

4. Safety is not the issue - statins are well-tolerated in ESRD 3. The issue is lack of efficacy for cardiovascular outcomes in prevalent dialysis patients

The Underlying Pathophysiology

The reason statins lose efficacy in dialysis patients likely relates to:

• Cardiovascular death in ESRD may not primarily result from atherosclerotic events 3
• Different mechanisms predominate: calcification, inflammation, volume overload, arrhythmias
• Lipid profiles in hemodialysis patients may not be as amenable to statin therapy 3

Practical Algorithm

Patient with ESRD → Check dialysis status
│
├─ Not on dialysis yet → INITIATE statin (if meets standard criteria)
│
└─ On dialysis → Check statin history
   │
   ├─ Already on statin before dialysis → CONTINUE statin
   │
   └─ Never on statin → DO NOT INITIATE
       (Exception: discuss with patient if very high LDL-C 
       or recent CV event, acknowledging uncertain benefit)

This approach is supported by both the 2014 KDIGO guidelines 1 and the 2018 AHA/ACC cholesterol guidelines 2, representing the current standard of care.